Prior to co-founding BIO-IB, Ashish was a Vice President in the Equity Capital Markets Group at ABN AMRO Rothschild. He brings substantial experience in origination and execution of public market transactions in the Healthcare sector. From 1997 to 2001, Ashish served as a Vice President at ING Barings where he was responsible for executing IPOs, Follow-ons, Pipes, Block Trades, and Private Equity issues.

Previously, Ashish worked as an Associate in the Equity Research Group at Furman Selz, a research-driven investment bank bought by ING in 1997. Ashish received a B.S. in Environmental Engineering from the University of Rochester and a certificate in Finance from the William E. Simon School of Business in 1994.

Prior to joining BIO-IB in December 2003, Aidan was a Vice President of Corporate Business Development at Elan Corporation plc. In this role Aidan was involved in a variety of corporate finance/ business development activities. He was a member of Elan’s Corporate Venture Capital group based in New York that made a series of strategic investments in public and private specialty pharma, biotechnology, device and diagnostic companies, in the U.S., Canada and Europe. He also was involved in corporate licensing and asset disposal activities.

Prior to joining Elan’s Corporate Venture Capital group, Aidan was head of Marketing for Elan's drug delivery division. In that role, Aidan was responsible for identifying and evaluating drug candidates for Elan's drug delivery technology platforms. Aidan has over 10 years experience in the pharmaceutical industry. He graduated from Trinity College, Dublin with a Bsc in Pharmacy and has an MBA from the Michael Smurfit Graduate School of Business, University College, Dublin. Aidan also holds the designation of Chartered Financial Analyst.

Prior to joining BIO-IB, Beth was the Managing Partner of Excellentia Global Partners, a global investment advisory group with a focus on China. Beth was the Managing Director and Co-Head of Global Capital Markets at ING-Barings. Prior to ING, she established and led the International Institutional Equity Group at Furman Selz. She also helped to establish the International Institutional presence for Morgan Stanley, and headed the teams at Lehman Brothers and Prudential Securities. 

Ms. Jacobs received an MBA in international finance from American University, Washington, D.C. in conjunction with the School of Foreign Service, and a BA Cum Laude from Boston College. Ms. Jacobs also attended Centre d’Etudes Internationale in Geneva, Switzerland.

Sena P. Lund has focused on the pharmaceutical and biotech sector for the last 8 years at Cathay Financial, and at ABN-AMRO and ING Barings. Prior to joining ING Barings, Sena worked as an analyst covering specialty and large cap pharmaceutical sectors (US and Europe) at Mehta Partners (formerly Mehta & Isaly) since 1998. In addition, Sena has broad experience in the financial arena having held positions at American Express Financial Advisors and TD Waterhouse. Sena holds an MBA and a CFA accreditation.

Harry brings a wealth of industry experience and has advised on numerous healthcare transactions. Harry was previously a Managing Director of Long Point Advisors LLC. Prior to forming Long Point Advisors, Harry was a senior managing director and U.S. head of technology capital markets at ABN AMRO, a top 20 global bank. As a senior investment banker at ABN AMRO from 1993-2002, he helped build ABN AMRO’s U.S. capital markets business, establish brand identity, and develop and manage transactions and client relationships in equities and debt capital markets.

Harry has significant experience advising Asian companies on international capital market activities and has travelled extensively throughout Asia. Harry received his B.A. degree from Knox College, M.B.A. from DePaul University and completed the Tuck Executive Program at Dartmouth. He is also a CPA. His business and professional affiliations include the AICPA and Financial Executives International. Harry is currently an adjunct faculty member in Finance in the MBA Program at Sacred Heart University.

Previous to BIO-IB, Niva was the licensing manager in the technology transfer office at Rockefeller University, marketing inventions from the University’s intellectual property portfolio to life science companies. Before joining Rockefeller she was a research analyst at Mehta Partners, a boutique research and advisory firm focused on the biotechnology and pharmaceutical industries. Niva obtained her Ph.D. in molecular biology from Rutgers University in 1994 and completed her post-doctoral training in molecular neurobiology at the Mount Sinai School of Medicine.

Prior to joining BIO-IB, Matthias has worked as an Associate Director in UBS Investment Bank’s Healthcare Group specializing in large-cap pharmaceuticals, specialty pharma, and biotech. Previous to UBS, he worked as an Associate in ABN Amro's Healthcare Group specializing in biotech and medical devices. Matthias has completed over 30 healthcare transactions including M&A, Debt and Equity Issuance, and Private Placements. Matthias has an MBA from Columbia University with a concentration in Finance and a B.S. in Biology from Stanford University.

Prior to joining BIO-IB, Steve worked as an Associate in the Wealth Management Department at U.S. Trust Company. At U.S. Trust, he was responsible for assisting portfolio managers and trust administrators with their clients’ investments and planning.

Steve is currently enrolled in the MBA program at Fordham University and will graduate in 2007 with concentrations in Finance and Accounting. In 2000, he received a Bachelors Degree from the University of Colorado, Boulder. Steve is Series 7 and 63 certified by the NASD.

Bill is President and Senior Managing Director at BIO-IB. Bill has been an investment banker and capital markets professional for 35 years and his transaction experience includes more than 1,000 transactions. Prior to joining the firm in March 2007, Bill was head of Equity Capital Markets at Putnam Lovell NBF Securities where he oversaw all transaction origination, execution, placement, pricing, and client and investor relationship development.

Prior to joining Putnam Lovell NBF, Bill was a Managing Director and Head of Equity Capital Markets/ Syndicate at ING Barings LLC in London. He served on the Board of Directors of the predecessor firm, Furman Selz LLC before it was acquired by ING Barings. Prior to joining Furman Selz, Bill spent eighteen years at Smith Barney, Inc. where he was the equity syndicate manager. Mr. Carson began his career as a corporate lending officer at Chase Manhattan Bank, N.A. Bill received a B.A. in Political Science from Hamilton College, Clinton, New York. He served in the U.S. Army as a First Lieutenant in U.S. Military Intelligence. He is a past President of the Investment Association of New York, an Officer and Governor of the Bond Club of New York, and former member of the Syndicate Committee of the Securities Industry Association.

Prior to re-joining BIO-IB, Austin worked as an Associate at Goldsmith Agio Helms & Lynner, a private investment bank focused on middle market mergers and acquisitions. While at Goldsmith Agio Helms, Austin assisted in structuring and executing sell-side engagements across a variety of industries.

Austin’s previous tenure with BIO-IB included work on some of the firms largest and most complicated transactions. Austin received an MBA from the Leonard N. Stern School of Business at New York University with a concentration in Finance and a Bachelors Degree in economics from the University of Maryland.